NCT05768932 2025-10-15BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaSillaJen, Inc.Phase 1 Recruiting260 enrolled
NCT02795182 2022-07-01Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesBeiGenePhase 1 Completed75 enrolled 17 charts